News Summary
NeutralBio-Techne's pending $11.3B acquisition by Merck KGaA at $73/share has cleared critical milestones including shareholder approval (Sept 23) and U.S. antitrust review (HSR expired Sept 18), with German regulatory clearance obtained. Underlying FY2026 results showed improving operational metrics (adjusted margins expanding to 32.2%, return to profitability with 17% net margin in Q4), though organic revenue growth remained flat and shareholders rejected executive compensation proposals.
Red flags
- •Flat organic revenue growth across multiple quarters (Q2 FY2026 flat year-over-year; organic growth trajectory unclear)
- •Shareholder rejection of merger-related executive compensation (79% voted against advisory proposal), signaling governance concerns
- •Deal completion contingent on pending international regulatory approvals beyond Germany; timeline and execution risk remains
Funds Reducing / Exiting (4)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Maverick Capital | Lee Ainslie | 1.5M | -3,203,927 | $108M | 2.9% | -68% | Existing |
| Durable Capital Partners | Henry Ellenbogen | 502K | -3,955,968 | $35M | 2.4% | -89% | Existing |
| Glenview Capital | Larry Robbins | 58K | -128,015 | $4M | 0.3% | -69% | Existing |
| Point72 | Steve Cohen | 0 | −295K | — | <0.1% | -100% | EXITED |
Shares Held reflects quarter-end positions for partial reductions. Funds that fully exited show 0 shares held. ∆ Shares is the change from the prior quarter. % of Fund is the prior-quarter position size — how much of the book was sold down.
Signal History
| Quarter | Direction | Funds | Score | vs SPY |
|---|---|---|---|---|
| Q2 2026 | SHORT | 4 | 3.86 | -1.2% |
| Q1 2026 | LONG | 3 | 3.85 | +19.1% |
Same issuer appearing in consecutive quarters — persistent institutional conviction. Returns are frozen at each archived quarter's last refresh.
Beneficial Ownership (13D/13G)
| Filer | Form | Shares | % of Class | Filed | Src |
|---|---|---|---|---|---|
| FMR LLC | SC 13G/A | 12.8M | 8.1% | 2026-08-06 | ↗ |
| FMR LLC | SC 13G | 7.9M | 5.0% | 2026-05-06 | ↗ |
| Vanguard Capital Management | SC 13G | 11.6M | 7.4% | 2026-04-29 | ↗ |
SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.